Literature DB >> 24843050

Very long-term results of electroanatomic-guided radiofrequency ablation of atrial arrhythmias in patients with surgically corrected atrial septal defect.

Marco Scaglione1, Domenico Caponi2, Elisa Ebrille3, Paolo Di Donna2, Francesca Di Clemente2, Alberto Battaglia3, Cristina Raimondo3, Manuela Appendino2, Fiorenzo Gaita3.   

Abstract

AIMS: Atrial tachycardias are common after repair of atrial septal defect (ASD). Although ablation has shown promising results in the short and mid-term follow-up, little data regarding the very long-term success exist. Our aim was to assess very long-term follow-up in patients who have undergone electroanatomic-guided radiofrequency (RF) ablation of late-onset atrial arrhythmias after ASD surgery. METHODS AND
RESULTS: Forty-six consecutive patients with surgically repaired ASD were referred for atrial tachycardia ablation. Electrophysiological (EP) study and ablation procedure with the aid of an electroanatomic mapping (EAM) system were performed. Mean age was 49 ± 13 years (females 61%). The presenting arrhythmias were typical atrial flutter (48%), atypical atrial flutter (35%), and atrial tachycardia (17%). In 41% of patients, atrial fibrillation was also present. The EP study showed a right atrial macroreentrant circuit in all the patients. In 12 of 46 (26%), the circuit was localized in the cavo-tricuspid isthmus, whereas in the remaining 34 patients (74%) was atriotomy-dependent. Acute success was 100%. Clinical arrhythmia recurred in 24% of the patients. Nine patients underwent a second and two a third ablation procedure, reaching an overall efficacy of 87% (40 of 46) at a mean follow-up of 7.3 ± 3.8 years since the last procedure. With antiarrhythmic drugs the success rate increased to 96% (44 of 46). No complications occurred.
CONCLUSION: In patients with surgically corrected ASD, EAM-guided RF ablation of late-onset macroreentrant atrial arrhythmias demonstrated a high success rate in a very long-term follow-up. Therefore, RF ablation could be considered early in the management of late-onset macroreentrant atrial tachycardias. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ablation; Atrial septal defect; Incisional tachycardias; Long-term follow-up

Mesh:

Year:  2014        PMID: 24843050     DOI: 10.1093/europace/euu076

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

1.  Supraventricular Arrhythmias in Patients with Adult Congenital Heart Disease.

Authors:  Carina Blomström Lundqvist; Tatjana S Potpara; Helena Malmborg
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 2.  Catheter Ablation of Incisional Atrial Tachycardia.

Authors:  Roman Tatarskiy; Svetlana Garkina; Dmitriy Lebedev
Journal:  J Atr Fibrillation       Date:  2016-10-31

3.  Ablation of Atrial Fibrillation in Patients with Congenital Heart Disease.

Authors:  Marwan M Refaat; Jad Ballout; Moussa Mansour
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-12

Review 4.  Procedural Feasibility and Long-Term Efficacy of Catheter Ablation of Atypical Atrial Flutters in a Wide Spectrum of Heart Diseases: An Updated Clinical Overview.

Authors:  Roberto De Ponti; Raffaella Marazzi; Manola Vilotta; Fabio Angeli; Jacopo Marazzato
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

5.  [Surface ECG characteristics of right and left atrial flutter].

Authors:  Thomas Rostock; Torsten Konrad; Sebastian Sonnenschein; Hanke Mollnau; Blanca Quesada Ocete; Karsten Bock; Raphael Spittler; Carola Huber; Cathrin Theis
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-08-11

6.  Management of scar-related atrial flutter in a patient with dextrocardia, inferior vena cava interruption, and azygos continuation.

Authors:  Veysel Kutay Vurgun; Başar Candemir; Ali Timuçin Altın; Ömer Akyürek
Journal:  Anatol J Cardiol       Date:  2018-02       Impact factor: 1.596

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.